DE2200976A1 - 1-Benzoyl-3,5-dimethylpyrazol enthaltende pharmazeutispche Zusammensetzungen - Google Patents
1-Benzoyl-3,5-dimethylpyrazol enthaltende pharmazeutispche ZusammensetzungenInfo
- Publication number
- DE2200976A1 DE2200976A1 DE19722200976 DE2200976A DE2200976A1 DE 2200976 A1 DE2200976 A1 DE 2200976A1 DE 19722200976 DE19722200976 DE 19722200976 DE 2200976 A DE2200976 A DE 2200976A DE 2200976 A1 DE2200976 A1 DE 2200976A1
- Authority
- DE
- Germany
- Prior art keywords
- benzoyl
- dimethylpyrazole
- pharmaceutical compositions
- compositions containing
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- AHNLSPFBSUPXHJ-UHFFFAOYSA-N (3,5-dimethylpyrazol-1-yl)-phenylmethanone Chemical compound N1=C(C)C=C(C)N1C(=O)C1=CC=CC=C1 AHNLSPFBSUPXHJ-UHFFFAOYSA-N 0.000 title claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- -1 1-benzoyl - 2,5-dimethylpyrazole Chemical compound 0.000 description 3
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940117173 croton oil Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- XEMRAKSQROQPBR-UHFFFAOYSA-N (trichloromethyl)benzene Chemical compound ClC(Cl)(Cl)C1=CC=CC=C1 XEMRAKSQROQPBR-UHFFFAOYSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000003243 anti-lipolytic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001884 corticosterones Chemical class 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008014 pharmaceutical binder Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7101228A FR2121461B1 (enExample) | 1971-01-15 | 1971-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2200976A1 true DE2200976A1 (de) | 1972-07-20 |
Family
ID=9070319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19722200976 Granted DE2200976A1 (de) | 1971-01-15 | 1972-01-10 | 1-Benzoyl-3,5-dimethylpyrazol enthaltende pharmazeutispche Zusammensetzungen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3743739A (enExample) |
| AU (1) | AU463887B2 (enExample) |
| BE (1) | BE778096A (enExample) |
| CA (1) | CA991080A (enExample) |
| DE (1) | DE2200976A1 (enExample) |
| FR (1) | FR2121461B1 (enExample) |
| GB (1) | GB1369704A (enExample) |
| IE (1) | IE35960B1 (enExample) |
| IL (1) | IL38381A (enExample) |
| OA (1) | OA04062A (enExample) |
| ZA (1) | ZA72250B (enExample) |
-
1971
- 1971-01-15 FR FR7101228A patent/FR2121461B1/fr not_active Expired
- 1971-12-16 IL IL38381A patent/IL38381A/xx unknown
- 1971-12-23 AU AU37264/71A patent/AU463887B2/en not_active Expired
-
1972
- 1972-01-06 CA CA131,844A patent/CA991080A/en not_active Expired
- 1972-01-06 IE IE19/72A patent/IE35960B1/xx unknown
- 1972-01-10 US US00216760A patent/US3743739A/en not_active Expired - Lifetime
- 1972-01-10 DE DE19722200976 patent/DE2200976A1/de active Granted
- 1972-01-10 OA OA54457A patent/OA04062A/xx unknown
- 1972-01-11 GB GB119272A patent/GB1369704A/en not_active Expired
- 1972-01-14 BE BE778096A patent/BE778096A/xx unknown
- 1972-01-14 ZA ZA720250A patent/ZA72250B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA72250B (en) | 1972-10-25 |
| US3743739A (en) | 1973-07-03 |
| BE778096A (fr) | 1972-07-14 |
| IE35960L (en) | 1972-07-15 |
| AU3726471A (en) | 1973-06-28 |
| AU463887B2 (en) | 1975-08-07 |
| CA991080A (en) | 1976-06-15 |
| IL38381A0 (en) | 1972-02-29 |
| OA04062A (fr) | 1979-10-30 |
| GB1369704A (en) | 1974-10-09 |
| FR2121461B1 (enExample) | 1974-03-22 |
| IE35960B1 (en) | 1976-07-07 |
| FR2121461A1 (enExample) | 1972-08-25 |
| IL38381A (en) | 1974-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69221686T2 (de) | Therapeutische und kosmetische zusammensetzungen zur hautbehandlung | |
| EP0279382B1 (de) | Warzenmittel | |
| US4353896A (en) | Penetrating topical medicament | |
| DE69317494T2 (de) | Zusammensetzungen, die mono oder polyhydroxylierte Aminosäuren zur Behandlung des Insulinunabhängigen Diabetes Mellitus enthalten | |
| DE3751761T2 (de) | Penetrationsverbesserer für die transdermale Verabreichung von systemisch wirksamen Arzneimitteln | |
| DE2818553A1 (de) | Zusammensetzung zur behandlung von proliferativen hautkrankheiten | |
| DE3413052A1 (de) | Pharmazeutische zubereitung und deren verwendung zur behandlung von hauterkrankungen | |
| DE69724629T2 (de) | Zusammensetzungen und deren verwendungen | |
| EP0206291A2 (de) | Aufsprühbare pharmazeutische Zubereitung für die topische Anwendung | |
| DE3705894A1 (de) | Pharmazeutische zusammensetzungen | |
| DE69511448T2 (de) | Verwendung von Phosphorsäurediester-Verbindungen zur Unterdrückung von Krebsmetastasen in der Leber | |
| EP0369216B1 (de) | Arzneimittelzubereitung aus Esterderivaten des Hecogenins und dessen Verwendung zur Behandlung von benigner Prostatahyperplasie | |
| EP0130524A2 (de) | Depot-Antiphlogistika | |
| DE69125204T2 (de) | Therapeutische Anwendung von Histamin-H3-Agonisten, neue Wirkstoffe und Verwendung zur Herstellung von Arzneimitteln | |
| DE60035613T2 (de) | Topische,kosmetische und pharmazeutische Mittel,enthaltend spezifische alkoxylierte Diester der Fumarsäure | |
| DE2200976A1 (de) | 1-Benzoyl-3,5-dimethylpyrazol enthaltende pharmazeutispche Zusammensetzungen | |
| EP0450123A1 (de) | Diclofenac-Natrium enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung | |
| DE3111770C2 (enExample) | ||
| DE2720420A1 (de) | Wirkstoffkombination gegen sonnenerythem und diese enthaltendes arzneimittel | |
| AT504040B1 (de) | Diclofenac-hältige zubereitung zur behandlung von verbrennungen | |
| DE3232882C2 (enExample) | ||
| DE2200976B (de) | 1 Benzoyl 3,5 dimethylpyrazol ent haltendes Antiphlogistikum | |
| EP0845983A2 (de) | Pharmazeutisches präparat mit trypanoziden eigenschaften | |
| DE4110087A1 (de) | Benfotiaminhaltiges arzneimittel und dessen verwendung | |
| DE69328585T2 (de) | Neue Alkaloidderivate, ihre Verwendung und diese enthaltende pharmazeutische Formulierungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| E77 | Valid patent as to the heymanns-index 1977 | ||
| 8339 | Ceased/non-payment of the annual fee |